A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization

被引:0
|
作者
Sara Marsango
Gianluigi Caltabiano
Mireia Jiménez-Rosés
Mark J. Millan
John D. Pediani
Richard J. Ward
Graeme Milligan
机构
[1] University of Glasgow,Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences
[2] Universitat Autònoma de Barcelona,Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina
[3] Centre for Innovation in Neuropsychiatry,Institut de Recherches Servier
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The dopamine D3 receptor (D3R) is a molecular target for both first-generation and several recently-developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial Intensity Distribution Analysis indicated that a substantial proportion of the receptor was present within dimeric/oligomeric complexes and that increased expression levels of the receptor favored a greater dimer to monomer ratio. Addition of the antipsychotics, spiperone or haloperidol, resulted in re-organization of D3R quaternary structure to promote monomerization. This action was dependent on ligand concentration and reversed upon drug washout. By contrast, a number of other antagonists with high affinity at the D3R, did not alter the dimer/monomer ratio. Molecular dynamics simulations following docking of each of the ligands into a model of the D3R derived from the available atomic level structure, and comparisons to the receptor in the absence of ligand, were undertaken. They showed that, in contrast to the other antagonists, spiperone and haloperidol respectively increased the atomic distance between reference α carbon atoms of transmembrane domains IV and V and I and II, both of which provide key interfaces for D3R dimerization. These results offer a molecular explanation for the distinctive ability of spiperone and haloperidol to disrupt D3R dimerization.
引用
收藏
相关论文
共 50 条
  • [1] A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization
    Marsango, Sara
    Caltabiano, Gianluigi
    Jimemez-Roses, Mireia
    Millan, Mark J.
    Pediani, John D.
    Ward, Richard J.
    Milligan, Graeme
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [2] Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
    Chien, Ellen Y. T.
    Liu, Wei
    Zhao, Qiang
    Katritch, Vsevolod
    Han, Gye Won
    Hanson, Michael A.
    Shi, Lei
    Newman, Amy Hauck
    Javitch, Jonathan A.
    Cherezov, Vadim
    Stevens, Raymond C.
    [J]. SCIENCE, 2010, 330 (6007) : 1091 - 1095
  • [3] Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D3 dopamine receptor over D2 dopamine receptor
    Appiah-Kubi, Patrick
    Olotu, Fisayo Andrew
    Soliman, Mahmoud E. S.
    [J]. JOURNAL OF MOLECULAR RECOGNITION, 2021, 34 (05)
  • [4] Dopamine D3 receptor ligands with antagonist properties
    Hackling, AE
    Stark, H
    [J]. CHEMBIOCHEM, 2002, 3 (10) : 946 - 961
  • [5] ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
    Bhathena, A.
    Wang, Y.
    Kraft, J. B.
    Idler, K. B.
    Abel, S. J.
    Holley-Shanks, R. R.
    Robieson, W. Z.
    Spear, B. B.
    Redden, L.
    Katz, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S76 - S76
  • [6] Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor
    Wood, MD
    Boyfield, I
    Nash, DJ
    Jewitt, FR
    Avenell, KY
    Riley, GJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (1-2) : 47 - 51
  • [7] Analysis of Human Dopamine D3 Receptor Quaternary Structure
    Marsango, Sara
    Caltabiano, Gianluigi
    Pou, Chantevy
    Varela Liste, Mara Jose
    Milligan, Graeme
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (24) : 15146 - 15162
  • [8] Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110
    Park, WK
    Jeong, D
    Yun, CW
    Lee, S
    Cho, H
    Kim, GD
    Koh, HY
    Pae, AN
    Cho, YS
    Choi, KI
    Jung, JY
    Jung, SH
    Kong, JY
    [J]. PHARMACOLOGICAL RESEARCH, 2003, 48 (06) : 615 - 622
  • [9] Anti parkinsonian actions of the selective dopamine D3 receptor antagonist S33084
    Silverdale, MA
    Millan, MJ
    Newman-Tancredi, A
    Crossman, AR
    Brotchie, JM
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02): : 215 - 215
  • [10] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90